Nedaplatin

奈达铂

Report date: 2023/02/09 16:46:06
NME

Base Information

Drug NameNedaplatin
Drug Alias Namenedaplatinum萘达铂顺糖氨铂nedaplatinoAqupla +[7] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionDNA inhibitors
TargetsDNA
Therapy Area/IndicationsUrinary Bladder NeoplasmsUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[9] 
Global Approved IndicationsUrinary Bladder NeoplasmsUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[8] 
Approved Indications in ChinaUrinary Bladder NeoplasmsUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[8] 
Original Approved Country/TerritoryJapan
Original Approved Date1995/01/01
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNichi-Iko Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuizhou Medical UniversityNichi-Iko Pharmaceutical Co LtdNanjing Simcere Dongyuan Pharmaceutical Co Ltd
Inactive CompaniesSun Yat-Sen University
Active IndicationsUrinary Bladder NeoplasmsUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XA
Related LinksWikipediaDrugBankKEGG